搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
sicklecellanemianews
2 天
5 pain management strategies that benefit our family
Columnist and caregiver Sylvia Amuta shares the top pain management strategies that help her young cousin cope with sickle ...
sicklecellanemianews
3 天
Phase 3 RISE UP study of mitapivat for SCD completes enrollment
Enrollment has finished for the Phase 3 RISE UP study, which is testing the oral therapy mitapivat in people with sickle cell ...
sicklecellanemianews
5 天
Upcoming Phase 2a trial to test oral desidustat in sickle cell disease
Approved in India as Oxemia for anemia, desidustat stimulates erythropoietin, a signaling molecule secreted in response to ...
sicklecellanemianews
12 天
Enlargement of heart’s left chamber tied to worse disease severity
Enlargement of the heart’s left upper chamber in sickle cell patients is associated with worse disease severity, per a new ...
sicklecellanemianews
17 天
Access to food, transportation key for sickle cell children: Study
Preschool-aged children with sickle cell disease with limited access to healthy food and transportation are at higher risk ...
sicklecellanemianews
10 天
Women with SCD face significant healthcare challenges: Study
Women with SCD experience significant healthcare challenges, a study found, with researchers calling for training on ...
sicklecellanemianews
10 天
Esteban Dominguez Cerezo,
Women with sickle cell disease (SCD) experience significant challenges with healthcare while struggling with both the ...
sicklecellanemianews
11 天
38 and counting: Thriving with sickle cell disease
Columnist Oluwatosin Adesoye reflects on her thriving life as she turns 38 (and counting) with sickle cell disease.
sicklecellanemianews
13 天
Oxbryta’s withdrawal is a setback in the fight against sickle cell disease
Wilson explains how Pfizer's decision to withdraw Oxbryta from global markets could affect the sickle cell community.
sicklecellanemianews
20 天
Desferal, to prevent iron overload in SCD patients, acquired by Mitem
Mitem Pharma has acquired worldwide rights to Desferal (deferoxamine), a therapy commonly used to lower excessive and damaging iron levels induced by blood transfusions in people with sickle cell ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈